Sanofi Sees Cemiplimab As Path To Relevance In Immuno-Oncology
The anti-PD-1 candidate is being developed in three cancer indications unserved by checkpoint inhibitors. Along with anti-CD38 isatuximab for multiple myeloma, this represents Sanofi's late push into IO.
You may also be interested in...
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.
A share purchase agreement for the sale of Zentiva has been signed with private equity group Advent, so Sanofi can concentrate on making the most of its new acquisitions.
Keeping Track: Keytruda Adds Two New Uses, Furoscix ‘Patch Pump’ Gets A CRL, And Nightstar Nabs An RMAT
The latest drug development news and highlights from our US FDA Performance Tracker.